The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.


The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.


Read more here: Moderna’s Covid vaccine offers vindication of its unconventional approach


Review clips: Yahoo Finance, CNBC



See acast.com/privacy for privacy and opt-out information.

Transcripts are not currently available for all podcasts, view our accessibility guide.

Copyright The Financial Times Limited 2022. All rights reserved.
Reuse this content (opens in new window) CommentsJump to comments section

Comments have not been enabled for this article.

Follow the topics in this podcast